SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).
暂无分享,去创建一个
A. D. Van den Abbeele | J. Fletcher | G. Demetri | R. Maki | M. Heinrich | C. Fletcher | C. Baum | J. Morgan | J. Desai | A. Kazanovicz | Jayesh Desai | A. D. Abbeele | C. D. Fletcher | M. Heinrich | Jonathan A Fletcher | Charles M. Baum | Robert G. Maki